Expanding the arsenal: Metformin for the treatment of triple-negative breast cancer?

Cell Cycle

Volumn 8, Issue 17, 2009, Pages 2681-

  Jiralerspong, Sao ^a   Angulo, Ana M Gonzalez ^a   Hung, Mien Chie ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; DRUG MECHANISM; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HUMAN; NOTE;

EID: 69749084991     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.17.9502     Document Type: Note

References (13)

1. Anders C, et al. Oncology 2008; 22:1233-1239
2. Liu B, et al. Cell Cycle 2009; 8:2031-2040
3. Pollak M. Nat Rev Cancer 2008; 8:915-928
4. Dowling RJ, et al. Cancer Res 2007; 67:10804-10812
5. Alimova IN, et al. Cell Cycle 2009; 8:909-915
6. Vazquez-Martin A, et al. Cell Cycle 2009; 8:88-96.
7. Zhuang Y, et al. J Mol Signal 2008; 3:18.
8. Sorlie, T. et al. Proc Natl Acad Sci USA 2001; 98:10869-10874
9. Rakha EA, et al. J Clin Oncol 2008; 26:2568-2581
10. Neve RM, et al. Cancer Cell 2006; 10:515-527
11. Jiralerspong S, et al. J Clin Oncol 2009.
12. Lee DF, et al. Int J Mol Med 2008; 22:633-638
13. Lee DF, et al. Cell 2007; 130:440-455